Showing results (51-60 of 121) with videos related to
Sort By:
Pageof 13
The Journal of Antimicrobial Chemotherapy|October 5, 2013
Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological responseNorihiro Furusyo, Eiichi Ogawa, Masayuki Murata, et al.Biochemical and Biophysical Research Communications|November 25, 2010
The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in miceEiichi Ogawa, Masaya Hosokawa, Norio Harada, et al.Diabetes Research and Clinical Practice|September 9, 2006
The spontaneously diabetic Torii rat with gastroenteropathyKotaro Yamada, Masaya Hosokawa, Shimpei Fujimoto, et al.BMJ Open Gastroenterology|July 14, 2018
Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysisBin Wei, Fanpu Ji, Yee Hui Yeo, et al.Hepatitis Research and Treatment|September 3, 2013
Interferon- α -Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV InfectionsShinji Shimoda, Kosuke Sumida, Sho Iwasaka, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|May 15, 2022
A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapyKosaku Sasaki, Masayuki Murata, Keiji Nakamura, et al.Atherosclerosis Plus|January 13, 2025
Impact of NAFLD-related SNPs on the carotid atherosclerosis development; a five-year prospective observational studyHiroaki Ikezaki, Ryoko Nakashima, Yuji Matsumoto, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|March 28, 2012
An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirinEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Journal of Hepatology|May 28, 2013
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapyEiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, et al.Journal of Hepatology|April 2, 2013
Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis CNorihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, et al.Pageof 13